TUSTIN, CA--(Marketwire - July 13, 2011) - Radient Pharmaceuticals Corporation “the Company” or “Radient” (OTCQX: RXPC) (PINKSHEETS: RXPC), a developer and marketer of In Vitro Diagnostic (IVD) cancer tests, announced today it has issued a Corporate Report. This 12-page document provides an overview of Radient’s business, its products, its markets, its strategy, and its finances. Investors or interested parties may view and download the report at the Company’s website at: Corporate Report.
Douglas MacLellan, Radient’s CEO indicated this new Corporate Report highlights investment catalysts in 5 key areas of Radient’s business. These catalysts include the Company’s:
-
Recent Focus on IVD Business
-
Multiple Revenue Stream Opportunities
-
Building Marketing & Distribution Channels for Approved Indications
-
Plan To Introduce IVDs for New Indications in US In Conjunction with CLIA Certified Labs
-
Intellectual Property Portfolio
For additional information on Radient Pharmaceuticals Corporation and its products visit: www.radient-pharma.com or e-mail info@radient-pharma.com. For Investor Relations contact Dilek Mir at: ir@radient-pharma.com or 714-881-0244.
The following table is intended to provide the latest information on Radient’s business metrics.
---------------------------------------------------------------------------- RPC’s Business Metrics ---------------------------------------------------------------------------- Cash on hand: $1.4 million* *Approximate amount as of July 11, 2011 ---------------------------------------------------------------------------- Shares Outstanding: 177 million* *Approximate number as of July 11, 2011 and there are 200 million shares fully authorized. ---------------------------------------------------------------------------- Outstanding Warrants & Options: 111.1 million* *Approximate number as of July 11, 2011 ----------------------------------------------------------------------------
About Radient Pharmaceuticals:
Headquartered in Tustin, California, Radient Pharmaceuticals Corporation is dedicated to saving lives and money for patients and global healthcare systems through the deployment of its FDA-cleared In Vitro Diagnostic Onko-Sure® cancer test kit for colorectal cancer treatment and recurrence monitoring. The Company’s focus is on the discovery, development and commercialization of unique high-value diagnostic tests that will help physicians answer important clinical questions related to early disease state detection, treatment strategy, and the monitoring of disease progression or recurrence. To learn more about our company, products, and potentially life-saving cancer test, visit www.radient-pharma.com.
Forward-Looking Statements:
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company’s operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.
Digg this 
Bookmark with del.icio.us 
Add to Newsvine
Technorati: in vitro diagnostics oncology cancer investors analyst report CLIA colorectal cancer
